X-linked adrenoleukodystrophy - Pipeline Insight, 2021
This report can be delivered to the clients within 24 Hours
DelveInsight’s, “X-linked adrenoleukodystrophy - Pipeline Insight, 2021,” report provides comprehensive insights about 3+ companies and 3+ pipeline drugs in X-linked adrenoleukodystrophy pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Geography Covered
X-linked adrenoleukodystrophy: Overview
X-linked adrenoleukodystrophy (ALD) is a rare genetic disorder that affects the white matter of the nervous system and the adrenal cortex. White matter is made up of nerve fibers called axons that relay nerve impulses from one cell to another. These nerve fibers are covered by myelin, an insulating layer or sheath that protects the nerve fibers. Myelin is made up of proteins and fats and gives white matter its white color. Without myelin, the signals between nerve cells cannot be transmitted properly, resulting in neurological symptoms. The adrenal cortex is the outer layer of cells of the adrenal glands. The adrenal glands sit atop the kidneys and produce hormones that are vital to proper health and development including cortisol and the sex hormones. Many of those affected experience serious neurological problems either during childhood or during adulthood with rather different types of disabilities.
'X-linked adrenoleukodystrophy - Pipeline Insight, 2021' report by DelveInsight outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the X-linked adrenoleukodystrophy pipeline landscape is provided which includes the disease overview and X-linked adrenoleukodystrophy treatment guidelines. The assessment part of the report embraces, in depth X-linked adrenoleukodystrophy commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, X-linked adrenoleukodystrophy collaborations, licensing, mergers and acquisition, funding, designations and other product related details.
Report Highlights
This segment of the X-linked adrenoleukodystrophy report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.
X-linked adrenoleukodystrophy Emerging Drugs
Further product details are provided in the report……..
X-linked adrenoleukodystrophy: Therapeutic Assessment
This segment of the report provides insights about the different X-linked adrenoleukodystrophy drugs segregated based on following parameters that define the scope of the report, such as:
X-linked adrenoleukodystrophy: Pipeline Development Activities
The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses X-linked adrenoleukodystrophy therapeutic drugs key players involved in developing key drugs.
Pipeline Development Activities
The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging X-linked adrenoleukodystrophy drugs.
X-linked adrenoleukodystrophy Report Insights
Current Treatment Scenario and Emerging Therapies:
DelveInsight’s, “X-linked adrenoleukodystrophy - Pipeline Insight, 2021,” report provides comprehensive insights about 3+ companies and 3+ pipeline drugs in X-linked adrenoleukodystrophy pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Geography Covered
- Global coverage
X-linked adrenoleukodystrophy: Overview
X-linked adrenoleukodystrophy (ALD) is a rare genetic disorder that affects the white matter of the nervous system and the adrenal cortex. White matter is made up of nerve fibers called axons that relay nerve impulses from one cell to another. These nerve fibers are covered by myelin, an insulating layer or sheath that protects the nerve fibers. Myelin is made up of proteins and fats and gives white matter its white color. Without myelin, the signals between nerve cells cannot be transmitted properly, resulting in neurological symptoms. The adrenal cortex is the outer layer of cells of the adrenal glands. The adrenal glands sit atop the kidneys and produce hormones that are vital to proper health and development including cortisol and the sex hormones. Many of those affected experience serious neurological problems either during childhood or during adulthood with rather different types of disabilities.
'X-linked adrenoleukodystrophy - Pipeline Insight, 2021' report by DelveInsight outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the X-linked adrenoleukodystrophy pipeline landscape is provided which includes the disease overview and X-linked adrenoleukodystrophy treatment guidelines. The assessment part of the report embraces, in depth X-linked adrenoleukodystrophy commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, X-linked adrenoleukodystrophy collaborations, licensing, mergers and acquisition, funding, designations and other product related details.
Report Highlights
- The companies and academics are working to assess challenges and seek opportunities that could influence X-linked adrenoleukodystrophy R&D. The therapies under development are focused on novel approaches to treat/improve X-linked adrenoleukodystrophy.
This segment of the X-linked adrenoleukodystrophy report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.
X-linked adrenoleukodystrophy Emerging Drugs
- Leriglitazone: Minoryx Therapeutics
- VK0214: Viking Therapeutics
Further product details are provided in the report……..
X-linked adrenoleukodystrophy: Therapeutic Assessment
This segment of the report provides insights about the different X-linked adrenoleukodystrophy drugs segregated based on following parameters that define the scope of the report, such as:
- Major Players in X-linked adrenoleukodystrophy
- Phases
- Late stage products (Phase III)
- Mid-stage products (Phase II)
- Early-stage product (Phase I) along with the details of
- Pre-clinical and Discovery stage candidates
- Discontinued & Inactive candidates
- Route of Administration
- Oral
- Parenteral
- intravenous
- Subcutaneous
- Topical.
- Molecule Type
- Monoclonal Antibody
- Peptides
- Polymer
- Small molecule
- Gene therapy
- Product Type
X-linked adrenoleukodystrophy: Pipeline Development Activities
The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses X-linked adrenoleukodystrophy therapeutic drugs key players involved in developing key drugs.
Pipeline Development Activities
The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging X-linked adrenoleukodystrophy drugs.
X-linked adrenoleukodystrophy Report Insights
- X-linked adrenoleukodystrophy Pipeline Analysis
- Therapeutic Assessment
- Unmet Needs
- Impact of Drugs
- Pipeline Product Profiles
- Therapeutic Assessment
- Pipeline Assessment
- Inactive drugs assessment
- Unmet Needs
Current Treatment Scenario and Emerging Therapies:
- How many companies are developing X-linked adrenoleukodystrophy drugs?
- How many X-linked adrenoleukodystrophy drugs are developed by each company?
- How many emerging drugs are in mid-stage, and late-stage of development for the treatment of X-linked adrenoleukodystrophy?
- What are the key collaborations (Industry–Industry, Industry–Academia), Mergers and acquisitions, licensing activities related to the X-linked adrenoleukodystrophy therapeutics?
- What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
- What are the clinical studies going on for X-linked adrenoleukodystrophy and their status?
- What are the key designations that have been granted to the emerging drugs?
- Minoryx Therapeutics
- Viking Therapeutics
- Poxel
- Orpheris
- Applied Genetic Technologies Corporation
- NEURALGENE
- Leriglitazone
- VK0214
- OP 101
- Research programme: Adrenoleukodystrophy gene therapy
- PRCN-323
Introduction
Executive Summary
X-linked adrenoleukodystrophy: Overview
Causes
Mechanism of Action
Signs and Symptoms
Diagnosis
Disease Management
Pipeline Therapeutics
Comparative Analysis
Therapeutic Assessment
Assessment by Product Type
Assessment by Stage and Product Type
Assessment by Route of Administration
Assessment by Stage and Route of Administration
Assessment by Molecule Type
Assessment by Stage and Molecule Type
Late Stage Products (Phase II/III)
Comparative Analysis
Leriglitazone: Minoryx Therapeutics
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report…..
Early Stage Products (Phase I)
Comparative Analysis
VK0214: Viking Therapeutics
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report…..
Inactive Products
Comparative Analysis
X-linked adrenoleukodystrophy Key Companies
X-linked adrenoleukodystrophy Key Products
X-linked adrenoleukodystrophy- Unmet Needs
X-linked adrenoleukodystrophy- Market Drivers and Barriers
X-linked adrenoleukodystrophy- Future Perspectives and Conclusion
X-linked adrenoleukodystrophy Analyst Views
X-linked adrenoleukodystrophy Key Companies
Appendix
Executive Summary
X-linked adrenoleukodystrophy: Overview
Causes
Mechanism of Action
Signs and Symptoms
Diagnosis
Disease Management
Pipeline Therapeutics
Comparative Analysis
Therapeutic Assessment
Assessment by Product Type
Assessment by Stage and Product Type
Assessment by Route of Administration
Assessment by Stage and Route of Administration
Assessment by Molecule Type
Assessment by Stage and Molecule Type
Late Stage Products (Phase II/III)
Comparative Analysis
Leriglitazone: Minoryx Therapeutics
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report…..
Early Stage Products (Phase I)
Comparative Analysis
VK0214: Viking Therapeutics
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report…..
Inactive Products
Comparative Analysis
X-linked adrenoleukodystrophy Key Companies
X-linked adrenoleukodystrophy Key Products
X-linked adrenoleukodystrophy- Unmet Needs
X-linked adrenoleukodystrophy- Market Drivers and Barriers
X-linked adrenoleukodystrophy- Future Perspectives and Conclusion
X-linked adrenoleukodystrophy Analyst Views
X-linked adrenoleukodystrophy Key Companies
Appendix
LIST OF TABLES
Table 1 Total Products for X-linked adrenoleukodystrophy
Table 2 Late Stage Products
Table 3 Mid Stage Products
Table 4 Early Stage Products
Table 5 Pre-clinical & Discovery Stage Products
Table 6 Assessment by Product Type
Table 7 Assessment by Stage and Product Type
Table 8 Assessment by Route of Administration
Table 9 Assessment by Stage and Route of Administration
Table 10 Assessment by Molecule Type
Table 11 Assessment by Stage and Molecule Type
Table 12 Inactive Products
Table 1 Total Products for X-linked adrenoleukodystrophy
Table 2 Late Stage Products
Table 3 Mid Stage Products
Table 4 Early Stage Products
Table 5 Pre-clinical & Discovery Stage Products
Table 6 Assessment by Product Type
Table 7 Assessment by Stage and Product Type
Table 8 Assessment by Route of Administration
Table 9 Assessment by Stage and Route of Administration
Table 10 Assessment by Molecule Type
Table 11 Assessment by Stage and Molecule Type
Table 12 Inactive Products
LIST OF FIGURES
Figure 1 Total Products for X-linked adrenoleukodystrophy
Figure 2 Late Stage Products
Figure 3 Mid Stage Products
Figure 4 Early Stage Products
Figure 5 Preclinical and Discovery Stage Products
Figure 6 Assessment by Product Type
Figure 7 Assessment by Stage and Product Type
Figure 8 Assessment by Route of Administration
Figure 9 Assessment by Stage and Route of Administration
Figure 10 Assessment by Molecule Type
Figure 11 Assessment by Stage and Molecule Type
Figure 12 Inactive Products
Figure 1 Total Products for X-linked adrenoleukodystrophy
Figure 2 Late Stage Products
Figure 3 Mid Stage Products
Figure 4 Early Stage Products
Figure 5 Preclinical and Discovery Stage Products
Figure 6 Assessment by Product Type
Figure 7 Assessment by Stage and Product Type
Figure 8 Assessment by Route of Administration
Figure 9 Assessment by Stage and Route of Administration
Figure 10 Assessment by Molecule Type
Figure 11 Assessment by Stage and Molecule Type
Figure 12 Inactive Products
